RC3H2

Across TCGA pan-cancer cohorts, RC3H2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RC3H2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RC3H2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RC3H2 expression acts as an unfavorable survival marker.

PDAC, LUAD, and LSCC are the cancer types where RC3H2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.526	0.923	<.001	34	view →
LUAD	DFS	Median	All	0.871	0.933	.008	25	view →
LSCC	DFS	Median	III,IV	0.882	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RC3H2–PDAC (DFS)

Open the PDAC breakdown →